Cyclo Therapeutics, Inc. (NasdaqGM: CYTH)
Health Care · Biotechnology · US
$—
— today · — 1Y
Cyclo Therapeutics, Inc. (NasdaqGM: CYTH) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Cyclo Therapeutics, Inc. across four factors: quality 14/100, growth 0/100. Its strongest factor is quality.
CYTH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $870.73K
- P/E
- —
- EPS
- -0.92
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 8
- Next earnings
- —
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease. Beyond its drug development pipeline, the firm engages in the sale of cyclodextrins and related commodities to sectors such as pharmaceuticals and nutrition, primarily for their application in diagnostics and specialized drug formulations. Originally established in 1990 as CTD Holdings, Inc., the company adopted its current name, Cyclo Therapeutics, Inc., in September 2019 and maintains its headquarters in Gainesville, Florida.
- ISIN
- US23254X1028
- Founded
- 1990
- Listed since
- May 3, 2000
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.28 | +0.29% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.52 | +0.15% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.77 | +0.70% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $551.83 | +0.77% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $835.53 | +0.85% |
| argenx SEENXTBR: ARGX | $63.06B | €878.20 | +1.62% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $153.20 | +10.30% |
Figures last refreshed Aug 18, 2026.